Webinar: Smooth Switch to the EAEU Marketing Authorization for Medicinal Products
The webinar will highlight the practical tips and guide you through the crucial steps of marketing authorization upgrade to the Eurasian Economic Union (EAEU) one, ultimately leading you towards a successful submission strategy development.
As of now, all national medicinal product marketing authorizations are valid in EAEU until their expiry date. However, the mentioned marketing authorizations must be revalidated according to the EAEU regulations until December 31st, 2025.
You will learn:
What do you need to prepare and implement now to timely and successfully transition to the EAEU marketing authorization?
- What are the main points you need to consider when going into the upgrade procedure?
- What do you need to know about EAEU GMP certification?
- What are the readability user testing requirements?
Preparing for a marketing authorization upgrade?
Create a successful submission strategy development. Explore your options in an informal chat.
Who Should Attend?
Professionals from the following fields:
- Regulatory Managers
- Regulatory Strategy Managers
- RA Partnerships Operations Manager
- QA Managers supporting RA
- RA Healthcare Compliance Managers
Duration: 45 min.
Speaker: Regulatory Affairs Project Manager CIS, Nargiz Asgarova, who will share her expertise regarding drug registration in the Eurasian Economic Union.
Regulatory Affairs Project Manager CIS
Other content that might interest you:
Regulatory Intelligence is a reliable and invaluable tool when it comes to pharmacovigilance. It's so important because it allows companies to remain up-to-date with the most recent drug safety data and identify new information quickly. What Is Regulatory...
Webinar: How does the conflict between UA & RU impact the pharma industry? Like the rest of the world, the pharmaceutical and biotech industries are beginning to worry about their ability to continue operations. And with good reason. Russia's invasion of Ukraine...
Like the rest of the world, the pharmaceutical and biotech industries are beginning to worry about their ability to continue operations. And, with good reason. Russia's invasion of Ukraine affects millions of people, not just in this Eastern European nation but...